文献速递骨软组织肉瘤与黑色素瘤

瑞戈非尼治疗晚期孤立性纤维性肿瘤:一项探索性II期临床研究结果

Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study.
PubMed 文献 · Eur J Cancer · 2023-10-18

意大利单中心探索性单臂II期试验评估瑞戈非尼在晚期进展性孤立性纤维性肿瘤(SFT)中的活性,2016年1月至2021年2月入组18例,16例可评估疗效。Choi标准客观缓解率37.5%(95%CI 15.2-64.6),RECIST标准部分缓解1/16(6.2%),中位无进展生存期4.7个月,1年无进展比例31.2%。

要点

  • 瑞戈非尼在晚期SFT中显示活性,Choi标准客观缓解率37.5%(95%CI 15.2-64.6)。
  • 6/16(37.5%)需确定性减量,去分化SFT未见缓解。
  • 中位无进展生存期4.7个月,1年无进展比例31.2%。

核心结论

  • 瑞戈非尼在SFT中显示活性,1年时30%患者无进展;在既往接受过其他抗血管生成药物治疗且难治的患者中也观察到缓解。
  • 但客观缓解率和中位无进展生存期低于其他抗血管生成药物的报告,可能归因于患者人群差异和高减量率。

研究设计与样本

  • 意大利单中心研究者发起的探索性单臂II期试验,评估瑞戈非尼在晚期进展性SFT成人患者中的活性,治疗至进展或限制性毒性。
  • 允许既往接受抗血管生成治疗;2016年1月至2021年2月入组18例(恶性SFT 13例,去分化SFT 4例,典型SFT 1例)。
  • 14例既往接受过治疗,其中12例接受过抗血管生成药物(中位治疗线数3);16例可评估疗效(1例筛选失败,1例早期终止)。

主要发现

  • 6/16(35.2%)需要确定性减量。
  • Choi标准客观缓解率37.5%(95%CI 15.2-64.6):部分缓解6/16(37.5%),疾病稳定6/16(37.5%),进展4/16(25%);6例缓解中5例发生于既往接受抗血管生成治疗的患者,去分化SFT未见缓解。
  • RECIST最佳疗效:部分缓解1/16(6.2%),疾病稳定12/16(75%),进展3/16(18.8%)。
  • 中位随访48.4个月时,Choi标准中位无进展生存期4.7个月(四分位距2.4-13.1),1年无进展患者比例31.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate the activity of regorafenib in advanced solitary fibrous tumour (SFT). METHODS: An Italian monocentric investigator-initiated exploratory single-arm Phase II trial was conducted of regorafenib in adult patients with advanced and progressive SFT, until progression or limiting toxicity. Prior treatment with antiangiogenics was allowed. Primary and secondary end-points were: overall response rate (ORR) by Choi criteria, and ORR by RECIST, progression-free survival (PFS), overall survival (OS). RESULTS: From January 2016 to February 2021, 18 patients were enroled [malignant-SFT = 13; dedifferentiated-SFT (D-SFT) = 4; typical-SFT (T-SFT) = 1]. Fourteen patients were pre-treated, in 12 cases with antiangiogenics (median [m-] lines of treatment = 3). Sixteen patients were evaluable for response (one screening failure; one early discontinuation). Six/16 (35.2%) required a definitive dose reduction. ORR by Choi was 37.5% (95% CI: 15.2-64.6), with 6/16 (37.5%) partial responses (PR), 6/16 (37.5%) stable disease (SD) and 4/16 (25%) progressions; 5/6 responses occurred in patients pre-treated with antiangiogenics. No responses were detected in D-SFT. Best RECIST responses were: 1/16 (6.2%) PR, 12/16 (75%) SD, 3/16 (18.8%) progressions. At 48.4 month m-FU, m-PFS by Choi was 4.7 (inter-quartile range: 2.4-13.1) months, with 31.2% patients progression-free at 1 year. CONCLUSION: Regorafenib showed activity in SFT, with 30% patients free-from-progression at one year. Responses were observed also in patients pretreated and refractory to another antiangiogenic agents. However, ORR and m-PFS were lower than reported with other antiangiogenics, and this was possibly due to discrepancies in the patient population and the high-rate of dose reductions.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Stacchiotti S, Baldi GG, Frezza AM, et al. Regorafenib in advanced solitary fibrous tumour: Results from an exploratory phase II clinical study. Eur J Cancer. 2023. PMID: 37918286. doi:10.1016/j.ejca.2023.113391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。